+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
57.1500
3.4662
3.4640
.0236
8.6851
18.7202
High
90.6113
2.0074
Yes
Yes
Yes
No
Yes
No
0.0
No
Yes
Yes
Yes
Combretastatin A4 (CA4) is a class of microtubule inhibitors derived from natural plants, first isolated from the southern African plant Combretum caffrum. As a natural product with significant antitumor activity, Compuritin inhibits microtubule polymerization by binding to the β-subunit of tubulin proteins, thereby disrupting the dynamic balance of the cytoskeleton and leading to cell cycle arrest and apoptosis. In recent years, with in-depth research into the pharmacological effects and molecular mechanisms of Compuratin, it has been found not only to show broad potential in the anti-tumor field, but also to demonstrate the ability to regulate related signaling pathways in various inflammatory and immune-related diseases such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, and psoriasis.
This paper aims to systematically review the chemical structure and physicochemical properties of Comprutin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, as well as its clinical application prospects, with the aim of providing a reference for research on the pharmacology of natural products and related disease treatments.
The chemical name of Comprutin A4 is 3-methoxy-4-methylstyrene-1,2-benzocinol, with the molecular formula C18H20O5 and a molecular weight of 316.3530. Its structural feature is that two aromatic rings are connected by a cis-vinyl bridge, forming a typical cis distyrene framework. This structure imparts strong hydrophobicity and high affinity for binding to β-tubulin.
In terms of physicochemical properties, the LogP value of compratin's LogP is 3.4662, indicating moderate lipid solubility, which facilitates cell membrane penetration. The polar surface area (TPSA) is 57.15 Ų, indicating moderate molecular polarity, which may affect its bioavailability and distribution characteristics. Low water solubility (0.0236 mg/mL) limits its direct oral absorption and in vivo distribution, but it is suitable for improving solubility through lipid carriers or nanoformulations. Notably, Compuritin has a high ability to penetrate the blood-brain barrier, which opens up potential applications in central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity, and the Ames-induced mutagenic test result was 0, indicating a low genotoxicity risk.
Comprehensive was originally isolated from the bark of Combretum caffrum (a plant in the South African Jasmine family). This plant is widely distributed in southern Africa, and its bark is rich in styrene-like compounds. Traditional extraction methods mainly use organic solvent extraction methods, commonly using methanol, ethanol, or ethyl acetate as extraction solvents.
The specific extraction process includes: drying and crushing the collected bark, then extracting using Soxhlet extraction or ultrasound-assisted extraction technology, followed by multi-step separation and purification through liquid-liquid partitioning and column chromatography, ultimately obtaining high-purity Compuritin A4. In recent years, with the development of green chemistry and efficient separation technologies, supercritical CO2 extraction, membrane separation technology, and high-performance liquid chromatography (HPLC) purification methods have been gradually applied to the extraction and purification of Compratin, significantly improving yield and purity.
In addition, considering the limitations of natural sources and environmental protection needs, chemical and semi-synthesis methods have been widely studied, especially for the synthesis of structurally modified derivatives, providing important pathways for Compuritin's drug development.
As a tubulin inhibitor, Compratin has multiple pharmacological activities, mainly including anti-tumor, anti-inflammatory, and immunomodulatory effects.
Compratin, by binding to β-tubulin (Kd about 0.4 μM), inhibits microtubule polymerization, blocks mitosis, induces tumor cell cycle stagnation at the G2/M phase, and promotes apoptosis. Its anti-tumor activity has been validated in various cancer models, including breast cancer, lung cancer, colorectal cancer, ovarian cancer, and brain tumors. In addition, Comprutin can also destroy the cytoskeleton of tumor vascular endothelial cells, causing tumor vessel collapse, inhibiting tumor blood flow, and enhancing anti-tumor effects.
Compuritin demonstrates the potential to regulate immune responses and inflammatory signaling pathways in inflammatory diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. Its targets involve key regulatory factors such as STAT3, TLR4, NFE2L2, and PRKCA, which can inhibit the expression of pro-inflammatory cytokines, reduce inflammatory responses, and regulate immune cell function.
In the atherosclerosis model, Compratin activates the AMPK signaling pathway, regulates lipid metabolism-related proteins such as ABCA1, inhibits LOX-1-mediated oxidized LDL uptake, and slows the progression of atherosclerosis. Additionally, its regulatory effect on the antioxidant enzyme system helps alleviate vascular endothelial damage.
The main mechanism of action of Compuratin is based on its high affinity for β-tubulin protein, blocking microtubule dynamic balance and leading to cytoskeletal disorders and cell cycle arrest. Microtubules, as important intracellular frameworks, participate in cell division, migration, and signal transduction. The inhibitory effect of Compritin directly leads to cell apoptosis and necrosis.
In addition to microtubule inhibition, compratin also regulates multiple signaling pathways involving various molecular targets:
Anti-tumor targets: MCL1, BCL2 (regulates apoptosis), STAT3 (promotes cell proliferation and immune escape), MMP2 (participates in tumor invasion), HIF1A (tumor hypoxia response), TOP1/TOP2A (DNA topoisomerase, affects DNA replication), MAPK1, ESR1, CYP19A1, etc.
Inflammatory and immune regulatory targets: TLR4 (inflammation signal receptor), NOTCH1 (cell differentiation regulation), PRKCA/PRKCD (protein kinase regulation), NFE2L2 (antioxidant response), ALOX5 (inflammatory mediator synthesis), STAT3, SIRT1 (cell stress response regulation), CASP9 (apoptotic execution protein), etc.
Metabolic and vascular protection targets: AMPK (energy metabolism regulation), ABCA1 (cholesterol transport), LOX-1 (oxidized low-density lipoprotein receptor), IDO1 (immune regulation), RECQ1 (DNA repair), etc.
The multi-target regulation of these targets enables Compritin to demonstrate multi-target, multi-mechanism therapeutic potential across various disease models.
Compritin's molecular weight is 316.3530, which fits the Lipinski rule molecular weight range. Its moderate LogP value of 3.4662 indicates good lipid solubility, which is beneficial for cell membrane penetration. The TPSA value is 57.15 Ų, which lies between polarity and hydrophobicity, which is beneficial for oral absorption and distribution in the body.
Low water solubility (0.0236 mg/mL) is a major bottleneck for the druggability of Compratin, limiting its oral bioavailability and formulation development. To address this, researchers have attempted to improve their solubility and stability through novel delivery systems such as nanoparticles, liposomes, and eutectics.
Pharmacokinetic studies show that Comprytin has a high blood-brain barrier penetration ability, suggesting its potential for central nervous system diseases. It does not inhibit hERG channels, reducing the risk of cardiotoxicity. A negative Ames test indicates a low genotoxicity risk.
Metabolism in the body mainly occurs through hepatic enzyme systems, and the activity and toxicity of these metabolites require further research. It has a moderate half-life and is suitable for multiple dosing regimens. Overall, Compassiritin has promising drug potential, but issues of water solubility and bioavailability need to be addressed.
The development of Compratin, as an antitumor drug, has entered clinical trial stages, especially its water-soluble prodrug CA4P (Combretastatin A4 phosphate), which has been widely studied due to its solubility and good pharmacokinetic properties. CA4P has demonstrated certain efficacy and safety in clinical trials for various solid tumors such as ovarian, lung, and kidney cancers, especially in combination chemotherapy and radiotherapy.
Beyond tumor treatment, Compratin's potential in inflammatory diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis is gradually emerging. Its regulation of signaling pathways such as STAT3, NFE2L2, and PRKCA offers new ideas for immune regulation and anti-inflammatory therapy. In the future, by combining precision medicine with targeted drug delivery technologies, Compratin is expected to become a candidate for multi-target therapy.
Moreover, the protective effect of Compuritin in atherosclerosis suggests its potential application in cardiovascular diseases, especially in regulating lipid metabolism and antioxidant stress. With deeper analysis of its mechanism of action, the design and optimization of compratin-related derivatives will further promote its clinical translation.
As a naturally derived microtubule inhibitor, Compratin, with its unique chemical structure and multi-target mechanism of action, demonstrates broad pharmacological activity in anti-tumor and various inflammatory and immunology-related diseases. Its good druggability parameters and low toxicity risk provide a solid foundation for clinical development. In the future, optimizing its water solubility and bioavailability, combined with innovations in nanotechnology and drug delivery systems, will greatly enhance the clinical application value of Compratin.
At the same time, its multi-target and multi-mechanism characteristics give Comprutin unique advantages in precision medicine and complex disease treatment. With ongoing basic and clinical research, Compass Peptide is expected to become an important representative in the field of natural product drug development, bringing new hope for the treatment of various diseases.
Shenshuai
Wenjing
Hedandan
